vs
Asana, Inc.（ASAN）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
Asana, Inc.的季度营收约是REPLIGEN CORP的1.0倍（$201.0M vs $197.9M），REPLIGEN CORP净利率更高（6.7% vs -34.0%，领先40.8%），REPLIGEN CORP同比增速更快（13.6% vs 9.3%），REPLIGEN CORP自由现金流更多（$17.6M vs $15.5M），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs 8.4%）
Asana是一家总部位于美国旧金山的软件企业，由达斯汀·莫斯科维茨和贾斯汀·罗森斯坦于2008年创立，核心产品是同名工作管理平台，支持网页端与移动端使用，可帮助团队梳理、跟踪及统筹各类工作事项，2012年4月正式商业化推出，2020年9月直接上市，当时估值达55亿美元。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
ASAN vs RGEN — 直观对比
营收规模更大
ASAN
是对方的1.0倍
$197.9M
营收增速更快
RGEN
高出4.3%
9.3%
净利率更高
RGEN
高出40.8%
-34.0%
自由现金流更多
RGEN
多$2.0M
$15.5M
两年增速更快
RGEN
近两年复合增速
8.4%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $201.0M | $197.9M |
| 净利润 | $-68.4M | $13.3M |
| 毛利率 | 88.9% | 52.5% |
| 营业利润率 | -34.8% | 9.0% |
| 净利率 | -34.0% | 6.7% |
| 营收同比 | 9.3% | 13.6% |
| 净利润同比 | -19.4% | 143.9% |
| 每股收益（稀释后） | $-0.29 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASANRGEN
| Q4 25 | $201.0M | $197.9M | ||
| Q3 25 | $196.9M | $188.8M | ||
| Q2 25 | $187.3M | $182.4M | ||
| Q1 25 | $188.3M | $169.2M | ||
| Q4 24 | $183.9M | $174.1M | ||
| Q3 24 | $179.2M | $154.9M | ||
| Q2 24 | $172.4M | $154.1M | ||
| Q1 24 | $171.1M | $151.3M |
净利润ASANRGEN
| Q4 25 | $-68.4M | $13.3M | ||
| Q3 25 | $-48.4M | $14.9M | ||
| Q2 25 | $-40.0M | $14.9M | ||
| Q1 25 | $-62.3M | $5.8M | ||
| Q4 24 | $-57.3M | $-30.3M | ||
| Q3 24 | $-72.2M | $-654.0K | ||
| Q2 24 | $-63.7M | $3.3M | ||
| Q1 24 | $-62.4M | $2.1M |
毛利率ASANRGEN
| Q4 25 | 88.9% | 52.5% | ||
| Q3 25 | 89.7% | 53.2% | ||
| Q2 25 | 89.7% | 50.0% | ||
| Q1 25 | 89.6% | 53.6% | ||
| Q4 24 | 89.2% | 26.1% | ||
| Q3 24 | 88.8% | 50.0% | ||
| Q2 24 | 89.7% | 49.8% | ||
| Q1 24 | 89.8% | 49.5% |
营业利润率ASANRGEN
| Q4 25 | -34.8% | 9.0% | ||
| Q3 25 | -25.1% | 8.9% | ||
| Q2 25 | -23.4% | 7.6% | ||
| Q1 25 | -33.8% | 3.9% | ||
| Q4 24 | -32.7% | -17.7% | ||
| Q3 24 | -42.9% | -5.1% | ||
| Q2 24 | -38.4% | 1.0% | ||
| Q1 24 | -39.7% | 1.3% |
净利率ASANRGEN
| Q4 25 | -34.0% | 6.7% | ||
| Q3 25 | -24.6% | 7.9% | ||
| Q2 25 | -21.4% | 8.2% | ||
| Q1 25 | -33.1% | 3.4% | ||
| Q4 24 | -31.2% | -17.4% | ||
| Q3 24 | -40.3% | -0.4% | ||
| Q2 24 | -37.0% | 2.2% | ||
| Q1 24 | -36.5% | 1.4% |
每股收益（稀释后）ASANRGEN
| Q4 25 | $-0.29 | $0.24 | ||
| Q3 25 | $-0.20 | $0.26 | ||
| Q2 25 | $-0.17 | $0.26 | ||
| Q1 25 | $-0.27 | $0.10 | ||
| Q4 24 | $-0.25 | $-0.55 | ||
| Q3 24 | $-0.31 | $-0.01 | ||
| Q2 24 | $-0.28 | $0.06 | ||
| Q1 24 | $-0.28 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $183.5M | $767.6M |
| 总债务越低越好 | — | $542.2M |
| 股东权益账面价值 | $188.4M | $2.1B |
| 总资产 | $840.4M | $2.9B |
| 负债/权益比越低杠杆越低 | — | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资ASANRGEN
| Q4 25 | $183.5M | $767.6M | ||
| Q3 25 | $184.1M | $748.7M | ||
| Q2 25 | $193.8M | $708.9M | ||
| Q1 25 | $184.7M | $697.2M | ||
| Q4 24 | $196.8M | $757.4M | ||
| Q3 24 | $219.4M | $784.0M | ||
| Q2 24 | $222.0M | $809.1M | ||
| Q1 24 | $236.7M | $780.6M |
总债务ASANRGEN
| Q4 25 | — | $542.2M | ||
| Q3 25 | — | $537.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $525.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ASANRGEN
| Q4 25 | $188.4M | $2.1B | ||
| Q3 25 | $224.6M | $2.1B | ||
| Q2 25 | $236.3M | $2.1B | ||
| Q1 25 | $227.5M | $2.0B | ||
| Q4 24 | $239.3M | $2.0B | ||
| Q3 24 | $291.9M | $2.0B | ||
| Q2 24 | $319.9M | $2.0B | ||
| Q1 24 | $326.4M | $2.0B |
总资产ASANRGEN
| Q4 25 | $840.4M | $2.9B | ||
| Q3 25 | $883.2M | $2.9B | ||
| Q2 25 | $877.1M | $2.9B | ||
| Q1 25 | $891.4M | $2.9B | ||
| Q4 24 | $874.2M | $2.8B | ||
| Q3 24 | $945.4M | $2.8B | ||
| Q2 24 | $978.2M | $2.9B | ||
| Q1 24 | $962.0M | $2.8B |
负债/权益比ASANRGEN
| Q4 25 | — | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $16.2M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $15.5M | $17.6M |
| 自由现金流率自由现金流/营收 | 7.7% | 8.9% |
| 资本支出强度资本支出/营收 | 0.3% | 4.1% |
| 现金转化率经营现金流/净利润 | — | 1.93× |
| 过去12个月自由现金流最近4个季度 | $74.5M | $93.9M |
8季度趋势，按日历期对齐
经营现金流ASANRGEN
| Q4 25 | $16.2M | $25.7M | ||
| Q3 25 | $39.8M | $48.1M | ||
| Q2 25 | $6.8M | $28.6M | ||
| Q1 25 | $15.9M | $15.0M | ||
| Q4 24 | $-14.9M | $39.2M | ||
| Q3 24 | $15.9M | $49.3M | ||
| Q2 24 | $-1.9M | $42.2M | ||
| Q1 24 | $-15.3M | $44.7M |
自由现金流ASANRGEN
| Q4 25 | $15.5M | $17.6M | ||
| Q3 25 | $38.5M | $43.4M | ||
| Q2 25 | $6.1M | $21.5M | ||
| Q1 25 | $14.3M | $11.4M | ||
| Q4 24 | $-16.3M | $33.6M | ||
| Q3 24 | $14.2M | $42.3M | ||
| Q2 24 | $-2.9M | $37.4M | ||
| Q1 24 | $-15.8M | $36.4M |
自由现金流率ASANRGEN
| Q4 25 | 7.7% | 8.9% | ||
| Q3 25 | 19.6% | 23.0% | ||
| Q2 25 | 3.3% | 11.8% | ||
| Q1 25 | 7.6% | 6.8% | ||
| Q4 24 | -8.8% | 19.3% | ||
| Q3 24 | 7.9% | 27.3% | ||
| Q2 24 | -1.7% | 24.3% | ||
| Q1 24 | -9.3% | 24.0% |
资本支出强度ASANRGEN
| Q4 25 | 0.3% | 4.1% | ||
| Q3 25 | 0.7% | 2.5% | ||
| Q2 25 | 0.3% | 3.9% | ||
| Q1 25 | 0.8% | 2.1% | ||
| Q4 24 | 0.7% | 3.2% | ||
| Q3 24 | 0.9% | 4.5% | ||
| Q2 24 | 0.6% | 3.1% | ||
| Q1 24 | 0.3% | 5.5% |
现金转化率ASANRGEN
| Q4 25 | — | 1.93× | ||
| Q3 25 | — | 3.23× | ||
| Q2 25 | — | 1.92× | ||
| Q1 25 | — | 2.57× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 12.70× | ||
| Q1 24 | — | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASAN
| US | $118.5M | 59% |
| Non Us | $82.5M | 41% |
RGEN
暂无分部数据
